Search - tctmd.com

Displaying 101 - 110 of 110

Sort: Relevancy | Date

Presentation TCT 2015

DCB in BTK Intervention: Summary of the Evidence From 2 Failed RCTs IN.PACT DEEP and BIOLUX P-II

Presenter: Gary M. Ansel, J. A. Mustapha

October 12, 2015

Presentation TCT 2015

The ILLUMINATE RCT: One-Year Outcomes

Presenter: William A. Gray, Peter A. Schneider, Mahmood K. Razavi

October 12, 2015

Presentation TCT 2015

Other Important TAVR Studies 2: The NOTION All-Comer TAVR RCT

Presenter: Samir R. Kapadia, Jeffrey J. Popma, Lars Sondergaard

October 11, 2015

Presentation TCT 2015

Status Update on Moderate-Risk TAVR RCTs 2: SURTAVI

Presenter: Martin B. Leon, Neil E. Moat, Patrick W. Serruys

October 11, 2015

Presentation TCT 2015

Status Update on Moderate-Risk TAVR RCTs 1: PARTNER IIA

Presenter: Martin B. Leon, Neil E. Moat

October 11, 2015

News Conference News TCT 2013

High-Dose Statins before PCI Improved Outcomes in NSTE-ACS

November 06, 2013

Presentation TCT 2013

Should Innovative New Device Platforms (Like Bioresorbable Scaffolds) Be Studied Using Global All-Comer "Big Data" Clinical Trials Rather Than Smaller Indication-Focused RCTs?

Presenter: Mitchell Krucoff

October 30, 2013

Presentation TCT 2013

Regulatory Approval Models for New TAVR "In Class" Devices: Are We Back to the Days of Device vs. Device RCTs?

Presenter: E. Murat Tuzcu

October 30, 2013

Presentation TCT 2013

Regulatory Approval Models for Iterative (Next Version) TAVR Devices: Do We Need RCTS or OPC-Controlled Registries?

Presenter: Jeffrey Popma

October 30, 2013

Presentation TCT 2013

The EVEREST II Randomized Controlled Trial (RCT): Three Year Outcomes

Presenter: Ted Feldman, Elyse Foster, Mansoor Qureshi, Brian Whisenant, John Williams, Donald Glower, Laura Mauri

January 31, 2013

Advertisement

DCB in BTK Intervention: Summary of the Evidence From 2 Failed RCTs IN.PACT DEEP and BIOLUX P-II

The ILLUMINATE RCT: One-Year Outcomes

Other Important TAVR Studies 2: The NOTION All-Comer TAVR RCT

Status Update on Moderate-Risk TAVR RCTs 2: SURTAVI

Status Update on Moderate-Risk TAVR RCTs 1: PARTNER IIA

High-Dose Statins before PCI Improved Outcomes in NSTE-ACS

Should Innovative New Device Platforms (Like Bioresorbable Scaffolds) Be Studied Using Global All-Comer "Big Data" Clinical Trials Rather Than Smaller Indication-Focused RCTs?

Regulatory Approval Models for New TAVR "In Class" Devices: Are We Back to the Days of Device vs. Device RCTs?

Regulatory Approval Models for Iterative (Next Version) TAVR Devices: Do We Need RCTS or OPC-Controlled Registries?

The EVEREST II Randomized Controlled Trial (RCT): Three Year Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content